publication date: Jul. 24, 2020
Conversation with The Cancer Letter
Jason Hafron: A major wake-up call to U.S. medicine to administer androgen deprivation therapy for prostate cancer on time
Jason M. Hafron, MD
Director of research, Michigan Institute of Urology;
Associate professor of urology, William Beaumont School of Medicine;
Director of robotic surgery, Beaumont Hospital Royal Oak
Jason M. Hafron, director of research at the Michigan Institute of Urology, was taken aback by the results of a study he was conducting: the vast majority of patients with prostate cancer who need regular injections to suppress their testosterone levels didn’t get treated on time.
“It’s shocking. No one’s really looked at U.S. data, ever, at this scale with over 22,000 patients and 84,000 injections,” Hafron, who is also associate professor of urology at the William Beaumont School of Medicine and director of robotic surgery at Beaumont Hospital Royal Oak, said to The Cancer Letter. “It definitely highlights a problem that we need to fix within our healthcare system.”
The study, conducted by researchers from more than a dozen institutions and published in The Journal of Urology, used real-world claims data to measure delivery of luteinizing hormone-releasing agonists in patients with prostate cancer from January 2007 through June 2016.
“This analysis underscores the importance of an appropriate dosing schedule to maintain sufficient levels of testosterone suppression,” Hafron said. “Inadequate testosterone suppression in advanced prostate cancer will lead to more treatment failure, shorter survival, and higher healthcare utilization. This has been well … Continue reading Jason Hafron: A major wake-up call to U.S. medicine to administer androgen deprivation therapy for prostate cancer on time
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.